TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update March 5, 2026
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 February 27, 2026
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition December 10, 2025
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update November 13, 2025
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 November 10, 2025
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 September 18, 2025
